Following the procedure described for the preparation of 4-methoxy-N-((1S)-1-{[((1S)-3-methoxy-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}propyl)amino]carbonyl}-4-methylpentyl)-1H-indole-2-carboxamide but substituting N-((1S)-1-{[((1S)-3-hydroxy-2-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}propyl)amino]carbonyl}-3,3-dimethylbutyl)-4-methoxy-1H-indole-2-carboxamide and making noncritical variations provided a crude product. This material was purified by Biotage MPLC (40S column, 2–5% methanol/chloroform) to afford 21 mg (9%) of the title compound as a pale tan solid. 1H NMR (400 MHz, DMSO-d6) δ 11.58 (s, 1H), 8.42 (d, J = 6.8 Hz, 1H), 7.62 (s, 1H), 7.32 (s, 1H), 7.08 (t, J = 7.7 Hz, 1H), 7.00 (d, J = 7.8 Hz, 1H), 6.49 (d, J = 7.3 Hz, 1H), 4.49–4.55 (m, 1H), 4.32–4.41 (m, 1H), 4.21–4.30 (m, 1H), 4.12 (t, J = 16.9 Hz, 1H), 3.87 (s, 3H), 3.23 (s, 3H), 3.01–3.16 (m, 2H), 2.20–2.32 (m, 1H), 2.03–2.15 (m, 1H), 1.87–1.98 (m, 1H), 1.73–1.85 (m, 1H), 1.54–1.70 (m, 3H), 0.93 (s, 9H); MS (ESI+) for C26H36N4O6m/z 501.2 (M + H)+; HRMS (ESI+) calcd for (M + H)+ 501.2708, found 501.2701.